2/20/2002 - Agilent Technologies Inc. (NYSE: A) today announced the release of the fourth in its series of cDNA microarray kits. The new kit is expected to provide pharmaceutical researchers with a reliable gene expression tool to study toxic side effects of new drugs much earlier in the drug discovery and development cycle, which could lead to personalized or safer therapies. The Agilent Rat cDNA Microarray Kit (G4105A) features sequence-verified cDNA clones from Incyte Genomics.
Previous Page | News by Category | News Search
If you found this page useful, bookmark and share it on: